Boston Scientific Taxus Inventory Of 150,000 Planned For U.S. Launch
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific projects a 60% U.S. drug-eluting stent market penetration "right out of the gate" for its soon-to-be-launched Taxus, according to Senior VP and Cardiovascular Group President Paul LaViolette
You may also be interested in...
Boston Scientific nabs French coverage
The French government will pay for Taxus Liberté after the drug-eluting stent received reimbursement approval on Feb. 15. The firm notes that the paclitaxel-eluting stent will now be available to patients at both private and public hospitals in France. The device was CE marked in September 2005. According to the firm, France was slow to adopt and reimburse the original Taxus stent (1"The Gray Sheet" Feb. 9, 2004, p. 20)...
Boston Scientific nabs French coverage
The French government will pay for Taxus Liberté after the drug-eluting stent received reimbursement approval on Feb. 15. The firm notes that the paclitaxel-eluting stent will now be available to patients at both private and public hospitals in France. The device was CE marked in September 2005. According to the firm, France was slow to adopt and reimburse the original Taxus stent (1"The Gray Sheet" Feb. 9, 2004, p. 20)...
Boston Sci/Nitromed NO more
Five-year R&D pact between device powerhouse and Lexington, Mass.-based pharmaceutical company expires without renewal Dec. 31. Boston Scientific and Nitromed were investigating the latter's nitric oxide (NO) technology as a potential complement to paclitaxel in Taxus stents (1"The Gray Sheet" Feb. 9, 2004, p. 20). A Nitromed rep described the exploratory project as "fruitful" but did not cite any resulting product development. The company is seeking other alliances in the device industry for development of its NO technology, which the firm believes could enhance current treatments for cardiovascular disease, pain and asthma...